Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2005;36:1415-1420
Published online before print June 9, 2005, doi: 10.1161/01.STR.0000170641.01047.cc
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
36/7/1415    most recent
01.STR.0000170641.01047.ccv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosell, A.
Right arrow Articles by Montaner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosell, A.
Right arrow Articles by Montaner, J.
Related Collections
Right arrow Acute Cerebral Infarction
Right arrow Embolic stroke
Right arrow Computerized tomography and Magnetic Resonance Imaging
Right arrow Thrombolysis
Right arrow Other Research

(Stroke. 2005;36:1415.)
© 2005 American Heart Association, Inc.


Original Contributions

A Matrix Metalloproteinase Protein Array Reveals a Strong Relation Between MMP-9 and MMP-13 With Diffusion-Weighted Image Lesion Increase in Human Stroke

Anna Rosell, MSc; José Alvarez-Sabín, MD, PhD; Juan F. Arenillas, MD, PhD; Alex Rovira, MD; Pilar Delgado, MD; Israel Fernández-Cadenas, MSc; Anna Penalba; Carlos A. Molina, MD, PhD Joan Montaner, MD, PhD

From the Neurovascular Research Laboratory, Neurovascular Unit and Neuroimaging Unit, Neurology Department, Universitat Autònoma de Barcelona, Hospital Vall d’Hebron, Barcelona, Spain.

Correspondence to Joan Montaner, Neurovascular Research Laboratory, Institut de Recerca, Hospital Vall d’Hebron, Pg Vall d’Hebron 119-129, 08035 Barcelona, Spain. E-mail 31862jmv{at}comb.es

Background and Purpose— Matrix metalloproteinases (MMPs) are involved in tissue destruction produced by the neuroinflammatory response that follows ischemic stroke. In the present study we use an MMP array to investigate the blood levels of several MMPs in stroke patients and its relation with brain tissue damage and neurological outcome.

Methods— Twenty-four patients with middle cerebral artery occlusion who received thrombolytic therapy were included. Blood samples were drawn before tissue plasminogen activator treatment and an MMP array (multiplex enzyme-linked immunosorbent assay [ELISA]) was performed including gelatinases (MMP-2 and MMP-9), collagenases (MMP-1, MMP-8, and MMP-13), stromelysines (MMP-3 and MMP-10), and MMP endogen inhibitors (TIMP-1 and TIMP-2). To assess tissue lesion a serial multimodal MRI study was performed (pretreatment and at 24 hours).

Results— Neither initial diffusion lesion nor hypoperfused volume was associated with metalloproteinase expression within the first 3 hours after stroke onset. Nevertheless, a strong correlation was found between MMP-9 and MMP-13 with diffusion-weighted image (DWI) lesion expansion (r=0.54, P=0.05 and r=0.60, P=0.017, respectively). Baseline levels of both MMP-9 (OR, 14;95% CI, 1.5 to 131; P=0.019) and MMP-13 (OR, 73; 95% CI, 3.9 to 1388; P=0.004) were independent predictors of final increase in brain infarct volume at 24 hours.

Conclusions— Our results demonstrate that within the neuroinflammatory response, high levels of MMP-9 and MMP-13 are involved in DWI lesion growth despite thrombolytic therapy, suggesting its ultra-early role in brain injury.


Key Words: fibrinolysis • metalloproteinase • magnetic resonance imaging, diffusion-weighted • stroke • tissue plasminogen activator




This article has been cited by other articles:


Home page
BrainHome page
B. D. Roussel, R. Macrez, A. Jullienne, V. Agin, E. Maubert, L. Dauphinot, M.-C. Potier, L. Plawinski, H. Castel, Y. Hommet, et al.
Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact
Brain, August 1, 2009; 132(8): 2219 - 2230.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. B. Holven, B. Halvorsen, V. Bjerkeli, J. K. Damas, K. Retterstol, L. Morkrid, L. Ose, P. Aukrust, and M. S. Nenseter
Impaired Inhibitory Effect of Interleukin-10 on the Balance Between Matrix Metalloproteinase-9 and Its Inhibitor in Mononuclear Cells From Hyperhomocysteinemic Subjects
Stroke, July 1, 2006; 37(7): 1731 - 1736.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. Rosell, A. Ortega-Aznar, J. Alvarez-Sabin, I. Fernandez-Cadenas, M. Ribo, C. A. Molina, E. H. Lo, and J. Montaner
Increased Brain Expression of Matrix Metalloproteinase-9 After Ischemic and Hemorrhagic Human Stroke
Stroke, June 1, 2006; 37(6): 1399 - 1406.
[Abstract] [Full Text] [PDF]